Noncoding RNA Gene Linked to Malignant Melanoma
|
By LabMedica International staff writers Posted on 05 Apr 2016 |

Image: Histopathology of a skin section from a patient with superficial spreading malignant melanoma (Photo courtesy of Profs. Leszek Wozniak and Krzysztof W. Zielinski).
While a large share of the human genome has long been considered “junk DNA” because it does not contribute to protein coding, recent insights indicate that it does produce many noncoding ribonucleic acids (RNAs) that play important roles in essential biological processes and diseases.
A remarkable link has been found between malignant melanoma and a noncoding RNA gene called SAMMSON. The SAMMSON gene is expressed in human malignant melanoma and, strikingly, the growth of aggressive skin cancer is highly dependent on this gene. The conclusions could pave the way for improved diagnostic tools and skin cancer treatment.
A European group of scientists led by those at the VIB, the Flanders Institute for Biotechnology (Leuven, Belgium) have shown that show that the recently annotated long noncoding RNA (lncRNA) gene SAMMSON is consistently co-gained with Microphthalmia-Associated Transcription Factor (MITF) gene. Their results indicate that silencing of the lineage addiction oncogene SAMMSON disrupts vital mitochondrial functions in a cancer-cell-specific manner; this silencing is therefore expected to deliver highly effective and tissue-restricted anti-melanoma therapeutic responses.
The scientists discovered a remarkable dependency of melanoma cells on SAMMSON expression. When reducing the presence of SAMMSON in melanoma cultures, cancer cells rapidly and massively die off, irrespective of the type of melanoma. This led to the key conclusion of a “SAMMSON addiction.” As the SAMSSON gene is not expressed in benign melanoma, its occurrence could be a key factor in developing new diagnostic tools that may dramatically improve melanoma prognosis.
Pieter Mestdagh, PhD, from Ghent University (Belgium) and a senior coauthor of the study, said, “Our study showed that the long noncoding RNA gene SAMMSON is specifically expressed in human melanomas and duplicated or amplified in about 10% of the cases. In addition, SAMMSON was nowhere to be found in melanocytes, the normal melanin-producing cells, nor in any other normal adult tissue. This unique expression profile of SAMMSON led us to hypothesize that this gene might play an important role in the etiology of melanoma.” The study was published on March 23, 2016, in the journal Nature.
Related Links:
VIB the Flanders Institute for Biotechnology
Ghent University
A remarkable link has been found between malignant melanoma and a noncoding RNA gene called SAMMSON. The SAMMSON gene is expressed in human malignant melanoma and, strikingly, the growth of aggressive skin cancer is highly dependent on this gene. The conclusions could pave the way for improved diagnostic tools and skin cancer treatment.
A European group of scientists led by those at the VIB, the Flanders Institute for Biotechnology (Leuven, Belgium) have shown that show that the recently annotated long noncoding RNA (lncRNA) gene SAMMSON is consistently co-gained with Microphthalmia-Associated Transcription Factor (MITF) gene. Their results indicate that silencing of the lineage addiction oncogene SAMMSON disrupts vital mitochondrial functions in a cancer-cell-specific manner; this silencing is therefore expected to deliver highly effective and tissue-restricted anti-melanoma therapeutic responses.
The scientists discovered a remarkable dependency of melanoma cells on SAMMSON expression. When reducing the presence of SAMMSON in melanoma cultures, cancer cells rapidly and massively die off, irrespective of the type of melanoma. This led to the key conclusion of a “SAMMSON addiction.” As the SAMSSON gene is not expressed in benign melanoma, its occurrence could be a key factor in developing new diagnostic tools that may dramatically improve melanoma prognosis.
Pieter Mestdagh, PhD, from Ghent University (Belgium) and a senior coauthor of the study, said, “Our study showed that the long noncoding RNA gene SAMMSON is specifically expressed in human melanomas and duplicated or amplified in about 10% of the cases. In addition, SAMMSON was nowhere to be found in melanocytes, the normal melanin-producing cells, nor in any other normal adult tissue. This unique expression profile of SAMMSON led us to hypothesize that this gene might play an important role in the etiology of melanoma.” The study was published on March 23, 2016, in the journal Nature.
Related Links:
VIB the Flanders Institute for Biotechnology
Ghent University
Latest Molecular Diagnostics News
- Molecular Vaginitis Panel Gains FDA Clearance and CLIA Waiver for Point-of-Care Use
- AI Tool Predicts Immunotherapy Response Using Tumor Senescence Signals
- New Variant Tracking Option Expands Molecular Residual Disease Monitoring
- Liquid Biopsy Detects Lung Cancer Recurrence Signals Months Before Imaging
- Streamlined Genetic Testing Speeds Pediatric Immune Disorder Diagnosis
- GeneDx Presents Evidence for Wider Clinical Use of Genomic Sequencing at ASHG 2026
- Clinical Trial Evaluates Liquid Biopsy for Early-Stage Breast Cancer Detection
- RNA-Based Test Predicts Immunotherapy Response in Non-Small Cell Lung Cancer
- Modeling Study Shows Blood-Based CRC Screening Could Prevent More Deaths Than Stool Tests
- Noninvasive Cervical Test Detects Endometrial Cancer for Triage
- AI Tool Classifies Pathogenic Variants in Severe Childhood Epilepsy
- Molecular Test Detects Barrett’s Esophagus to Guide Endoscopy Referral
- Blood-Based Metagenomic Test Detects Wide Range of Pathogens from Single Sample
- New RNA Detection Tool Shows Promise for HIV and Other Viral Testing
- Tissue-Specific Vesicle Isolation Expands Molecular Insights Into Liver Disease
- Whole Genome Sequencing Solution Targets Unsolved Rare Disease Cases
Channels
Clinical Chemistry
view channel
Point-of-Care Blood Biomarker Test Detects Brain Injury Missed by CT
Traumatic brain injury remains difficult to assess in emergency settings because some patients continue to have symptoms despite normal computed tomography findings. Approximately 2.8 million people in the U.... Read more
Daily Blood Testing May Help Guide Earlier Antibiotic Stopping in Sepsis
Sepsis is a life-threatening condition caused by the body’s overwhelming response to infection and accounts for thousands of deaths each year. In intensive care, concern about stopping treatment too early... Read moreHematology
view channel
New Myelofibrosis Guidelines Recommend Expanded Genetic Testing at Diagnosis
Myelofibrosis is a rare, life-threatening blood cancer affecting up to six per 100,000 people. The disease causes scarring in the bone marrow, limiting the production of healthy blood cells and potentially... Read more
Handheld Point-of-Care Test Aims to Enable Rapid Coagulation Assessment in Trauma
Severe blood loss and inadequate tissue oxygenation are leading causes of preventable death after traumatic injury. Blood products are essential in trauma care, but cold-chain storage, short shelf life,... Read moreImmunology
view channel
Antibody Profiling Predicts Inflammatory Bowel Disease Years Before Diagnosis
Inflammatory bowel disease (IBD), which includes Crohn’s disease and ulcerative colitis, involves abnormal immune responses that cause persistent inflammation and damage in the digestive system.... Read more
Immune Profiling Initiative Aims to Improve Bone Marrow Analysis in Leukemia
Acute myeloid leukemia (AML) is an aggressive blood cancer in which assessing disease burden after therapy can help guide clinical evaluation. Patients with measurable residual disease (MRD) after treatment... Read more
Immune Profiling Identifies Early Maternal Autoantibodies Linked to Preterm Birth Risk
A typical pregnancy lasts about 40 weeks, but labor begins prematurely in roughly one in 10 pregnancies. Preterm birth is the leading cause of newborn death worldwide, yet its underlying causes and which... Read more
Longitudinal Blood Testing Reveals Changes in Allergen Sensitization During Childhood
Food allergy is a major childhood health concern, and distinguishing persistent risk from transient sensitization can guide clinical decisions. Specific IgE antibodies may be detectable even when a child... Read moreMicrobiology
view channel
Molecular Panel Gains WHO Emergency Use Listing to Support Ebola Outbreak Response
The ongoing Ebola Bundibugyo outbreak in the Democratic Republic of the Congo and neighboring countries has become one of the largest outbreaks of this Ebola virus species recorded to date.... Read more
Rapid Host-Response Test Aims to Predict Corticosteroid Benefit in Sepsis
Sepsis and severe infections are difficult to treat because patients with similar clinical presentations may have very different underlying immune responses. Corticosteroids are commonly used in severe... Read morePathology
view channel
Digital Pathology Test Stratifies Recurrence Risk in Early Breast Cancer
In hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative early breast cancer, accurate recurrence-risk assessment helps guide treatment decisions. However, individual risks... Read more
AI Pathology Tool Predicts DNA Repair Deficiency in High-Grade Serous Ovarian Cancer
High-grade serous tubo-ovarian carcinoma is an aggressive cancer arising in the ovaries or fallopian tubes. Some tumors exhibit homologous recombination deficiency (HRD), a feature reflecting impaired DNA repair.... Read moreTechnology
view channel
New AI-Powered System Aims to Streamline Laboratory and Manufacturing Workflows
Scientific laboratories supporting drug development, biotechnology, and materials research increasingly rely on coordinated digital workflows to move data, samples, and activities across teams.... Read moreLaser-Based Swab Analysis Shows Promise for Detecting Disease-Linked Odor Patterns
Disease-related changes in volatile organic compounds can alter body odor, producing measurable patterns in exhaled breath and bodily fluids. Current analytical methods can be complex, time-consuming,... Read moreIndustry
view channel
Hologic and Inpeco Partner to Advance Molecular Laboratory Automation in Europe
Hologic, Inc. (Marlborough, MA, USA) and Inpeco S.A. (Novazzano, Switzerland) have signed a co-marketing partnership in Europe for Inpeco’s recently launched FlexLab X automation solution and Hologic’s... Read more
Collaboration to Expand Cervical Cancer Screening Access With At-Home HPV Collection
Cervical cancer is largely preventable with regular screening and early detection of human papillomavirus (HPV), the leading cause of the disease. Screening gaps persist, in part because traditional sample... Read more
Alzheimer’s Progression Blood Test Gains U.S. Patent Ahead of Planned Launch
Alzheimer’s disease is the most common cause of dementia, accounting for an estimated 60–70% of cases worldwide. Its progressive effects on memory, thinking, behavior, and daily functioning underscore... Read more







